Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 43 clinical trials
None
  • 718 views
  • 01 Dec, 2021
  • 157 locations
None
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation

The purpose of the study is to learn whether the study drug (capmatinib) helps to control lung cancer better compared to a single agent chemotherapy (docetaxel) and whether it is safe when given to patients suffering from a particular type of lung cancer. This type of cancer is called non-small …

epidermal growth factor
epidermal growth factor receptor
EGFR
cancer chemotherapy
docetaxel
  • 0 views
  • 19 Nov, 2021
  • 53 locations
None
Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)

ROS1 rearrangements are present in 1-2% of NSCLC cases and define a distinct molecular subgroup. Like ALK (anaplastic lymphoma kinase) rearrangements in NSCLC, ROS1 fusions confer sensitivity to

  • 0 views
  • 07 Jun, 2021
  • 39 locations
None
Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC

A Phase 4 study to assess Overall and Intracranial Response Rate of single-agent lorlatinib in participants with advanced ALK-positive NSCLC whose disease has progressed on alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI)therapy.

administration intravenous
renal function
cancer
kinase inhibitor
metastatic non-small cell lung cancer
  • 0 views
  • 02 Dec, 2021
  • 40 locations
None
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK ROS1 OR NTRK1-3 Alterations

Phase 1 will evaluate the safety and tolerability at different dose levels of repotrectinib in pediatric and young adult subjects with advanced or metastatic malignancies harboring anaplastic

chemotherapy regimen
solid tumour
tyrosine
ROS1
measurable disease
  • 0 views
  • 14 Nov, 2021
  • 26 locations
None
Efficacy Comparison of Dostarlimab Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

participants with non-squamous NSCLC without a known sensitizing epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or receptor tyrosine kinase-1 (ROS-1) mutation, BRAF V600E mutation

squamous non-small cell lung cancer
EGFR
alopecia
carboplatin
growth factor
  • 2 views
  • 24 Oct, 2021
  • 48 locations
None
Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients

This study includes patients diagnosed with a metastatic non small cell lung cancer (NSCLC) with anaplastic lymphoma kinase (ALK) translocation. The standard treatment for patients with

progressive disease
neutrophil count
serum bilirubin level
cancer chemotherapy
brigatinib
  • 0 views
  • 21 Jul, 2021
  • 21 locations
None
Program to Establish the Genetic and Immunologic Profile of Patient's Tumor for All Types of Advanced Cancer

It is a non-randomized, multicentric, cohort study, combined with a biological sample collection, a clinical data collection and with a genetic and immunologic biomarkers study. The ProfiLER program aims to implement a personalized cancer medicine approach by proposing to establish the genetic and immunologic profile of the tumor for patients …

advanced cancer
primary cancer
x-rays
  • 12 views
  • 16 Aug, 2021
  • 8 locations
None
A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Brigatinib is a medicine that binds to the surface of tumor cells in some cancers and delivers a dose of chemotherapy directly to the tumor. In this study, participants will be people with non-small-cell lung cancer (NSCLC for short). The main aim of the study is to learn if brigatinib …

  • 19 views
  • 30 Oct, 2021
  • 122 locations
None
Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)

This ALCHEMIST trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

nivolumab
gemcitabine
lung cancer
cancer
carcinoma
  • 1114 views
  • 01 Dec, 2021
  • 1142 locations